Description
The implantable Brain-Computer Interface (BCI) sector is rapidly transitioning from the laboratory to the clinic, with an estimated Total Addressable Market projected to reach $80 billion by the end of the decade. As companies enter Phase 2 and Phase 3 pivotal trials for devices capable of restoring communication and motor control to patients with severe neurologic impairments, our specialty faces a critical infrastructure gap. Just as PM&R historically secured its dominance in spasticity management by proving that surgical and pharmacological interventions require specialized post-acute functional rehabilitation, we must now define the standard of care for BCI neuro-decoding. If physiatrists do not rapidly establish the multidisciplinary care models for these patients, we risk ceding this highly complex phase of recovery—and its associated reimbursement pathways—to other specialties. This session serves as a national market-readiness briefing and a strategic call-to-arms for the AAPM&R Neuro-Technology and BCI Community. Attendees will receive a comprehensive overview of the current BCI hardware landscape, contrasting legacy penetrating arrays with novel endovascular and minimally invasive surface technologies. Furthermore, the session will explicitly outline the "institutional site-readiness" requirements for rehabilitation hospitals aiming to host multi-center corporate clinical trials. Finally, we will outline the community's roadmap for drafting national consensus guidelines ahead of the 2026 Technology Summit, providing attendees with direct avenues to join the committee, shape policy, and position their local institutions at the forefront of this neuro-rehabilitation paradigm shift.
Learning Objectives
After completing this live activity, the participant should be able to:
- Describe the current clinical landscape of implantable Brain-Computer Interface (BCI) hardware, accurately differentiating between penetrating, surface, and endovascular delivery systems.
- Define the critical role of the physiatrist as the mandatory clinical team lead in post-acute BCI neuro-decoding and functional adaptation.
- List the specific institutional site-readiness requirements—including IT cybersecurity protocols, ICU step-down capabilities, and dedicated research coordination—necessary for rehabilitation hospitals to host corporate BCI clinical trials.
- Discuss the strategic necessity of developing national AAPM&R consensus guidelines to secure appropriate CPT coding, dictate the standard of care, and ensure adequate Medicare reimbursement for complex neuro-technology rehabilitation.
Accreditation Statement
The American Academy of Physical Medicine and Rehabilitation (AAPM&R) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Credit Designation
The American Academy of Physical Medicine and Rehabilitation (AAPM&R) designates this live activityfor a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Statement
In accordance with ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, AAPM&R requires all individuals who are in a position to affect the strategic direction of AAPM&R and/or control the content of an educational activity to disclose all financial relationships with any ineligible company within the last 24 months. The ACCME defines an “ineligible company” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Disclosures are made in written form prior to the start of the educational activity, and any potential conflicts of interest that exist are mitigated prior to the start of the activity through AAPM&R’s Conflict of Interest Disclosure and Resolution Policy Process. Individuals in a position to affect the strategic direction of AAPM&R and/or control content and their disclosed financial relationships are listed below.
No other planners, faculty, or individuals in control of content disclosed any relevant financial relationships.
Principle Faculty
Name, Credential(s): Company Name, Nature of financial relationship;
Liang Chen MD, MPH, FAAPMR - Nothing to Disclose
AAPM&R Medical Education Committee
Name, Credential(s): Company Name, Nature of financial relationship
Rachel Brakke Holman, MD - Nothing to Disclose
Sarah M. Eickmeyer, MD - Nothing to Disclose
Chelsea D. Frost, MD, MS - Nothing to Disclose
David J. Haustein, MBA,MD,MBA - Relationships to Disclose
Sarah K. Hwang, MD - Nothing to Disclose
Ravi E. Kasi, MD - Nothing to Disclose
Caroline Pupke, DO - Nothing to Disclose
Monica E. Rho, MD - Nothing to Disclose
McCasey R. Smith, MD - Nothing to Disclose
Jennifer A. Soo Hoo, MD - Nothing to Disclose
Brionn K. Tonkin, MD - Nothing to Disclose
Stephanie Tow, MD - Nothing to Disclose
Justin L. Weppner, DO - Nothing to Disclose
Alexandra G. Wolfe, DO - Nothing to Disclose
FDA Disclosures
All faculty members for this activity have disclosed they do not intend to discuss or demonstrate any pharmaceutical or medical device for which FDA clearance has not been approved.